AU2019370363B2 - Amino acid compositions and methods for treating cystic fibrosis - Google Patents

Amino acid compositions and methods for treating cystic fibrosis Download PDF

Info

Publication number
AU2019370363B2
AU2019370363B2 AU2019370363A AU2019370363A AU2019370363B2 AU 2019370363 B2 AU2019370363 B2 AU 2019370363B2 AU 2019370363 A AU2019370363 A AU 2019370363A AU 2019370363 A AU2019370363 A AU 2019370363A AU 2019370363 B2 AU2019370363 B2 AU 2019370363B2
Authority
AU
Australia
Prior art keywords
cftr
leu
ile
ser
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019370363A
Other languages
English (en)
Other versions
AU2019370363A1 (en
Inventor
Astrid GROSCHE
Shanshan LIN
Sreekala PRABHAKARAN
Sadasivan Vidyasagar
Xiaodong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2019370363A1 publication Critical patent/AU2019370363A1/en
Application granted granted Critical
Publication of AU2019370363B2 publication Critical patent/AU2019370363B2/en
Priority to AU2025248660A priority Critical patent/AU2025248660A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2019370363A 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis Active AU2019370363B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025248660A AU2025248660A1 (en) 2018-10-30 2025-10-08 Amino acid compositions and methods for treating cystic fibrosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
US62/752,847 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025248660A Division AU2025248660A1 (en) 2018-10-30 2025-10-08 Amino acid compositions and methods for treating cystic fibrosis

Publications (2)

Publication Number Publication Date
AU2019370363A1 AU2019370363A1 (en) 2021-05-13
AU2019370363B2 true AU2019370363B2 (en) 2025-07-10

Family

ID=70464502

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019370363A Active AU2019370363B2 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis
AU2025248660A Abandoned AU2025248660A1 (en) 2018-10-30 2025-10-08 Amino acid compositions and methods for treating cystic fibrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025248660A Abandoned AU2025248660A1 (en) 2018-10-30 2025-10-08 Amino acid compositions and methods for treating cystic fibrosis

Country Status (10)

Country Link
US (1) US12220400B2 (https=)
EP (1) EP3873453A4 (https=)
JP (2) JP7689492B2 (https=)
KR (1) KR20210086660A (https=)
CN (1) CN113164425A (https=)
AU (2) AU2019370363B2 (https=)
BR (1) BR112021008395A2 (https=)
CA (1) CA3116015A1 (https=)
MX (1) MX2021005113A (https=)
WO (1) WO2020092639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192756A1 (en) * 2001-08-08 2004-09-30 Franco Conti Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the opthalmic field
WO2016191263A1 (en) * 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL FOR TREATING MUCOVISCIDOSE AND TECHNIQUES AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THESE
AU2003901316A0 (en) * 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
ITTO20080443A1 (it) 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
CA3001099A1 (en) * 2015-10-09 2017-04-13 Abbvie S.A.R.L. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
MA45397A (fr) * 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192756A1 (en) * 2001-08-08 2004-09-30 Franco Conti Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the opthalmic field
WO2016191263A1 (en) * 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis

Also Published As

Publication number Publication date
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
KR20210086660A (ko) 2021-07-08
AU2025248660A1 (en) 2025-10-30
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US12220400B2 (en) 2025-02-11
JP7689492B2 (ja) 2025-06-06
CN113164425A (zh) 2021-07-23
JP2025128185A (ja) 2025-09-02
CA3116015A1 (en) 2020-05-07
MX2021005113A (es) 2021-06-15
US20210393584A1 (en) 2021-12-23
WO2020092639A1 (en) 2020-05-07
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
AU2025248660A1 (en) Amino acid compositions and methods for treating cystic fibrosis
Rotin et al. Function and regulation of the epithelial Na+ channel ENaC
Lee et al. Taste receptors in innate immunity
Scott et al. SPX-101 is a novel epithelial sodium channel–targeted therapeutic for cystic fibrosis that restores mucus transport
Czikora et al. A novel tumor necrosis factor–mediated mechanism of direct epithelial sodium channel activation
US5840702A (en) Cystic fibrosis treatment
US20110111014A1 (en) Methods and compositions for treatment of neurological disorders
US20020115619A1 (en) Compositions and methods for treatment of cystic fibrosis
JP6672139B2 (ja) 粘液の粘性の正常化のための組成物
Schwiebert et al. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein
WO2007109648A2 (en) Compositions and methods for modulating store-operated calcium entry
WO2019070759A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
Park et al. Leptin suppresses glutamate-induced apoptosis through regulation of ERK1/2 signaling pathways in rat primary astrocytes
Wu et al. CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
US11149071B2 (en) Fusion protein Slit2D2(C386S)-HSA and use thereof in prevention and/or treatment of lung inflammation
AU2002322475B2 (en) Blocking peptide for inflammatory cell secretion
JP7630540B2 (ja) 神経保護ペプチド
US11028137B2 (en) Mutant islet amyloid polypeptides with improved solubility and methods for using the same
Ren et al. Nicotinic acetylcholine receptor (nAChR) dependent chorda tympani taste nerve responses to nicotine, ethanol and acetylcholine
EP3554527A1 (en) Saline formulations of splunc1 peptides
Sawczak et al. Novel approaches for potential therapy of cystic fibrosis
US5834421A (en) Methods and compositions for treating cystic fibrosis
KR20250114044A (ko) 만성 호흡기 질환 치료약
CN118490828A (zh) Oxgr1受体激动剂促进肺黏液纤毛清除系统功能
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)